Poly(2‐Hydroxyethyl Methacrylate) Hydrogel‐Based Microneedles for Metformin Release

The release of metformin, a drug used in the treatment cancer and diabetes, from poly(2-hydroxyethyl methacrylate), pHEMA, hydrogel-based microneedle patches is demonstrated vitro. Tuning composition pHEMA hydrogels enables preparation robust with mechanical properties such that they would penetrate skin (insertion force single to be ≈40 N). Swelling experiments conducted at 20, 35, 60 °C show temperature-dependent degrees swelling diffusion kinetics. Drug microneedles fitted various models (e.g., zero order, first second order). Such have potential application for transdermal delivery metformin aging, cancer, etc.